Mariner, LLC Bristol Myers Squibb CO Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mariner, LLC holds 867,736 shares of BMY stock, worth $50.1 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

867,736

Previous 989,863 12.34%

Holding current value

$50.1 Million

Previous $41.1 Million 9.23%

% of portfolio

0.08%

Previous 0.08%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$39.66 - $51.75 $4.84 Million - $6.32 Million	-122,127 Reduced 12.34%	867,736 $44.9 Million
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $16.4 Million - $21.6 Million	-408,329 Reduced 29.2%	989,863 $41.1 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $11.5 Million - $13.1 Million	-240,057 Reduced 14.65%	1,398,192 $75.8 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $2.17 Million - $2.58 Million	-44,678 Reduced 2.65%	1,638,249 $84.1 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $7.85 Million - $8.78 Million	-135,646 Reduced 7.46%	1,682,927 $97.7 Million
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $9.9 Million - $11 Million	-155,340 Reduced 7.87%	1,818,573 $116 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $8.84 Million - $10 Million	134,535 Added 7.31%	1,973,913 $137 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $21.5 Million - $25.5 Million	314,314 Added 20.61%	1,839,378 $132 Million
Q3 2022 Nov 10, 2022	SELL	$0.13 - $76.84 $8,155 - $4.82 Million	-62,732 Reduced 3.95%	1,525,064 $108 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $5.03 Million - $5.54 Million	-69,232 Reduced 4.18%	1,587,796 $122 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $728,230 - $873,213	-11,845 Reduced 0.71%	1,657,028 $121 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $45.3 Million - $52.8 Million	845,304 Added 102.64%	1,668,873 $104 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $3.57 Million - $4.18 Million	60,290 Added 7.9%	823,569 $48.7 Million
Q2 2021 Aug 24, 2021	BUY	$61.91 - $67.42 $1.17 Million - $1.27 Million	18,906 Added 2.54%	763,279 $51 Million
Q1 2021 May 07, 2021	SELL	$59.34 - $66.74 $1.9 Million - $2.14 Million	-32,012 Reduced 4.12%	744,373 $47 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $4.42 Million - $5 Million	76,474 Added 10.93%	776,385 $48.2 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $8.95 Million - $9.92 Million	155,827 Added 28.64%	699,911 $42.2 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $21.9 Million - $25.6 Million	399,127 Added 275.34%	544,084 $32 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $303,363 - $440,857	6,538 Added 4.72%	144,957 $8.08 Million
Q4 2019 Feb 13, 2020	BUY	$49.21 - $64.19 $2.17 Million - $2.83 Million	44,040 Added 46.66%	138,419 $8.89 Million
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $94,992 - $112,626	-2,221 Reduced 2.3%	94,379 $4.79 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $598,309 - $661,600	13,409 Added 16.12%	96,600 $4.38 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $576,949 - $687,940	12,787 Added 18.16%	83,191 $3.97 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $1.29 Million - $1.67 Million	26,453 Added 60.19%	70,404 $3.66 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $16,888 - $19,048	-306 Reduced 0.69%	43,951 $2.73 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $365,685 - $455,786	7,237 Added 19.55%	44,257 $2.45 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $248,907 - $286,542	-4,154 Reduced 10.09%	37,020 $2.34 Million
Q4 2017 Feb 09, 2018	BUY	$59.94 - $65.35 $70,489 - $76,851	1,176 Added 2.94%	41,174 $2.52 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $2.21 Million - $2.55 Million	39,998	39,998 $2.55 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account